A Canadian expert panel report recommends public coverage of the gene therapy Kymriah if its cost goes down, the Globe and Mail reports.
Kymriah, a CAR-T therapy from Novartis, has been approved by Health Canada to treat acute lymphoblastic leukemia in children and diffuse large B-cell lymphoma in adults, it notes.